Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14084016 | 0.89 | P2RX1 (0.51) | TRPV1NPC1RAB9AP2RX1ABL1 | |
| SCHEMBL14083890 | 0.88 | TRPV1 (0.77) | TRPV1ABL1MAPTHTT | |
| SCHEMBL14083714 | 0.86 | P2RX1 (0.51) | TRPV1NPC1RAB9ANAMPTP2RX1 | |
| SCHEMBL14083465 | 0.86 | TRPV1 (0.63) | TRPV1NPC1RAB9AGRM4ALDH1A1 | |
| SCHEMBL14083893 | 0.85 | TRPV1 (0.61) | TRPV1NPC1RAB9AGRM4BRAF | |
| SCHEMBL14083837 | 0.84 | NPC1 (0.56) | TRPV1NPC1RAB9AP2RX1ABL1 | |
| SCHEMBL14083920 | 0.84 | TRPV1 (0.60) | TRPV1NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL14083888 | 0.84 | TRPV1 (0.79) | TRPV1MAPTTSHR | |
| SCHEMBL14083475 | 0.82 | TRPV1 (0.65) | TRPV1NPC1RAB9AGRM4MAPT | |
| SCHEMBL14083872 | 0.80 | TRPV1 (0.63) | TRPV1NPC1RAB9AGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673342-A2 | AMIDES THAT INHIBIT VANILLOID RECEPROT SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2006-06-28 | — | — | EP | claimed |
| US-7037927-B2 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2006-05-02 | — | — | US | claimed |
| WO-2005040121-A2 | AMIDES THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2005-05-06 | — | — | WO | claimed |
| US-20050085512-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-04-21 | — | — | US | claimed |
| US-7595332-B2 | Amides that inhibit vanilloid receptor subtype 1 (VR1) | ABBOTT LABORATORIES (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| EP-1673342-A2 | AMIDES THAT INHIBIT VANILLOID RECEPROT SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060122231-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) | ABBVIE INC. | 2006-06-08 | — | — | US | disclosed |
| US-7037927-B2 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2006-05-02 | — | — | US | disclosed |
| WO-2005040121-A2 | AMIDES THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20050085512-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885NPC1 1061/4885RAB9A 1914/4885 |
| US-20060122231-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) | TRPV1, OPRL1, AVPR2 | TRPV1 1/4885NPC1 4042/4885RAB9A 2621/4885 |
| US-20050085512-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, OPRL1, AVPR1A | TRPV1 1/4885NPC1 3942/4885RAB9A 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.